fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether and oxidopamine

fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether has been researched along with oxidopamine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Duty, S; O'Neill, MJ; Visanji, NP	1

Other Studies

1 other study(ies) available for fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether and oxidopamine

Article	Year
Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology, 2006, Volume: 51, Issue:3 Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Brain Injuries; Cell Count; Dose-Response Relationship, Drug; Drug Interactions; Ethers; Hydrocarbons, Fluorinated; Immunohistochemistry; Male; Medial Forebrain Bundle; Nicotine; Nicotinic Agonists; Oxidopamine; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase	2006

Article

Year

Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle.

Neuropharmacology, 2006, Volume: 51, Issue:3

Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Brain Injuries; Cell Count; Dose-Response Relationship, Drug; Drug Interactions; Ethers; Hydrocarbons, Fluorinated; Immunohistochemistry; Male; Medial Forebrain Bundle; Nicotine; Nicotinic Agonists; Oxidopamine; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase

2006